Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
6.47
+0.06 (0.94%)
At close: Oct 21, 2025, 4:00 PM EDT
6.35
-0.12 (-1.85%)
After-hours: Oct 21, 2025, 6:02 PM EDT
Coya Therapeutics Revenue
Coya Therapeutics had revenue of $163.62K in the quarter ending June 30, 2025, a decrease of -95.22%. This brings the company's revenue in the last twelve months to $423.45K, down -95.57% year-over-year. In the year 2024, Coya Therapeutics had annual revenue of $3.55M, down -40.79%.
Revenue (ttm)
$423.45K
Revenue Growth
-95.57%
P/S Ratio
248.40
Revenue / Employee
$52,932
Employees
8
Market Cap
108.21M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3.55M | -2.45M | -40.79% |
Dec 31, 2023 | 6.00M | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 92.15B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
COYA News
- 14 days ago - Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function - Business Wire
- 22 days ago - Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia - PRNewsWire
- 4 weeks ago - Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis - PRNewsWire
- 5 weeks ago - Coya Therapeutics' COYA 303 Shows Promising Central Nervous System (CNS) Anti-inflammatory Effects and Systemic Regulatory T Cell (Treg) Enhancing Effects in a Preclinical Animal Inflammation Model - PRNewsWire
- 6 weeks ago - Coya Therapeutics' COYA 302 ALS Trial Accepted by NEALS as a NEALS-Affiliated Trial - PRNewsWire
- 6 weeks ago - PRISM MarketView Features Exclusive Q&A with Coya Therapeutics CEO Arun Swaminathan on Targeting Neurodegenerative Diseases Through Treg Therapies - GlobeNewsWire
- 6 weeks ago - Coya Therapeutics to Participate at Upcoming September Investor Conferences - PRNewsWire
- 2 months ago - Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) - PRNewsWire